Get notified when DMRA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The auditor's report includes a going-concern warning, indicating substantial doubt about Galecto's ability to continue operating.
NASDAQ: DMRA Damora Therapeutics, Inc. 424B5

Damora Therapeutics prices $275M IPO at $19/share; net proceeds $257.2M to fund antibody programs

Filed February 11, 2026 · ~1 min read

Key Changes

  • high

    Damora Therapeutics is offering 14,473,685 primary shares at $19.00 per share, raising $275.0M gross; net proceeds to the company are $257.2M.

    The Offering verify on EDGAR →
  • high

    Net proceeds will fund preclinical studies, clinical trials, and manufacturing for antibody programs, including Phase 3 development of DMR-001, with broad management discretion.

    Use of Proceeds verify on EDGAR →
  • high

    Investors face immediate dilution of $11.68 per share; pro forma as-adjusted net tangible book value is $11.68 per share.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.

Partner

Trade DMRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify